Full Press Release Details
BridgeBio Pharma Reports First Quarter 2024 Financial Results And Business Update.
BBIO
BridgeBio Pharma Reports First Quarter 2024 Financial Results And Business Update
Key Takeaway: BridgeBio Pharma Reports First Quarter 2024 Financial Results And Business Update
Price reaction · baseline $27.79 (2024-05-07 close) · hit after-hours · 1 other BBIO headline(s) in the window, move may be shared
day 0 close
-0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis